Switch theme
Sign up to access all valuation multiples
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
2017
72
Last FY Revenue n/a
LTM EBITDA -$98.2M
$16K
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lexeo Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$98.2M.
In the most recent fiscal year, Lexeo Therapeutics achieved revenue of n/a and an EBITDA of -$96.2M.
Lexeo Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lexeo Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$98.2M | XXX | -$96.2M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$106M | XXX | -$106M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$101M | XXX | -$98.3M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Lexeo Therapeutics's stock price is $3.
Lexeo Therapeutics has current market cap of $90.4M, and EV of $16K.
See Lexeo Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $16K | $90.4M | XXX | XXX | XXX | XXX | $-2.90 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Lexeo Therapeutics has market cap of $90.4M and EV of $16K.
Lexeo Therapeutics's trades at n/a EV/Revenue multiple, and -0.0x EV/EBITDA.
Equity research analysts estimate Lexeo Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lexeo Therapeutics has a P/E ratio of -0.9x.
See valuation multiples for Lexeo Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $90.4M | XXX | $90.4M | XXX | XXX | XXX |
| EV (current) | $16K | XXX | $16K | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.0x | XXX | -0.0x | XXX | XXX | XXX |
| EV/EBIT | -0.0x | XXX | -0.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.9x | XXX | -0.9x | XXX | XXX | XXX |
| EV/FCF | -0.0x | XXX | -0.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLexeo Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.5M for the same period.
Lexeo Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Lexeo Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Lexeo Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -16% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lexeo Therapeutics acquired XXX companies to date.
Last acquisition by Lexeo Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Lexeo Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Lexeo Therapeutics founded? | Lexeo Therapeutics was founded in 2017. |
| Where is Lexeo Therapeutics headquartered? | Lexeo Therapeutics is headquartered in United States of America. |
| How many employees does Lexeo Therapeutics have? | As of today, Lexeo Therapeutics has 72 employees. |
| Who is the CEO of Lexeo Therapeutics? | Lexeo Therapeutics's CEO is Mr. Richard Nolan Townsend. |
| Is Lexeo Therapeutics publicy listed? | Yes, Lexeo Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Lexeo Therapeutics? | Lexeo Therapeutics trades under LXEO ticker. |
| When did Lexeo Therapeutics go public? | Lexeo Therapeutics went public in 2023. |
| Who are competitors of Lexeo Therapeutics? | Similar companies to Lexeo Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Lexeo Therapeutics? | Lexeo Therapeutics's current market cap is $90.4M |
| Is Lexeo Therapeutics profitable? | Yes, Lexeo Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Lexeo Therapeutics? | Lexeo Therapeutics's last 12 months EBITDA is -$98.2M. |
| What is the current EV/EBITDA multiple of Lexeo Therapeutics? | Current EBITDA multiple of Lexeo Therapeutics is -0.0x. |
| What is the current FCF of Lexeo Therapeutics? | Lexeo Therapeutics's last 12 months FCF is -$90.7M. |
| What is the current EV/FCF multiple of Lexeo Therapeutics? | Current FCF multiple of Lexeo Therapeutics is -0.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
